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Background: Elevated circulating levels of the protein galectin-3, a mediator of fibrogenesis, have pre-
viously been associated with adverse outcomes in heart failure (HF) patients and appear to modify
response to certain pharmacologic therapies. This study investigated the relationship between galectin-3
level and clinical outcomes in HF patients randomized to implantable cardioverter defibrillator (ICD-
only) or cardiac resynchronization therapy (CRT-D).
Methods and Results: Plasma galectin-3 concentrations weremeasured in 654NewYorkHeart Association
functional class I/II patients participating in the MADIT-CRT trial. A heterogeneity of response was detected
between pre-implantation galectin-3 and randomization group (CRT-D or ICD-only) on the primary
MADIT-CRT trial end point of nonfatal HF event or death (P 5 .045). Among patients with baseline
galectin-3 levels in the top quartile of the distribution, CRT-D was associated with a 65% reduction in risk of
the primary end point (hazard ratio [HR] 0.35, 95% confidence interval [CI] 0.19e0.67), whereas among pa-
tients with lower baseline galectin-3 values CRT-D was associated with a 25% decrease in risk (HR 0.75,
95%CI. 0.51e1.11). Baseline galectin-3 level alsowas observed to be an independent predictor of the primary
end point (multivariable adjusted HR per log unit increase: 1.55; 95% CI 1.01e2.38; P5 .043).
Conclusions: Elevated galectin-3 was found to be an independent predictor of adverse HF outcome in
patients with mildly symptomatic HF. A significant interaction of device randomization group with pre-
implantation galectin-3 level was detected, with HF patients with the highest baseline galectin-3 levels
deriving a disproportionately larger benefit from CRT-D. (J Cardiac Fail 2014;20:793e799)
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793galectin-3 was shown to promote cardiac fibrosis, fibroblast
proliferation, collagen production, hypertrophy, and
dysfunction.6,7 Increased circulating galectin-3 levels
may, therefore, reflect active and excessive myocardial fi-
brogenesis in patients with heart failure (HF). Several
recent studies have reported an association between
elevated circulating galectin-3 with cardiac ventricular re-
modeling as well as adverse clinical outcomes in patients
with HF.8e12 Patients with elevated baseline galectin-3
were also observed to be less likely to respond to statin
therapy in a retrospective analysis of the Controlled Rosu-
vastatin in Multinational Trial in Heart Failure (CORONA),
and to angiotensin II receptor antagonist therapy in a retro-
spective analysis of the Valsartan Heart Failure Trial
(ValHeFT).13,14
Multiple large randomized trials have demonstrated the
benefit of implantable cardioverter defibrillators (ICDs)
794 Journal of Cardiac Failure Vol. 20 No. 11 November 2014with cardiac resynchronization therapy (CRT-D) in
reducing morbidity and mortality in HF and in improving
left ventricular geometry.15e19 Although active myocardial
fibrosis and inflammation are thought to play important
roles in ventricular remodeling in HF, the extent to which
the benefit of CRT-D may relate to baseline fibrogenesis
is unknown.
In the present study, we examined the relationship among
plasma galectin-3 concentration, CRT-D, and clinical
outcome in a large subset of patients with HF who partici-
pated in the Multicenter Automatic Defibrillator Implanta-
tion Trial With Cardiac Resynchronization Therapy
(MADIT-CRT).
Methods
Study Population
The design and primary results of MADIT-CRT have been re-
ported previously.17,20 In brief, MADIT-CRT was a multicenter,
controlled, parallel-group study, with an imbalanced randomiza-
tion (3:2, CRT with ICD or ICD-only, respectively), that was con-
ducted in the United States (88 sites), Canada (2 sites), and Europe
(20 sites). A total of 1,820 HF patients were enrolled with ejection
fractions #30%, an ischemic etiology and New York Heart Asso-
ciation (NYHA) functional class I or II symptoms, or a nonische-
mic etiology and NYHA functional class II symptoms, and QRS
durations $130 ms.
The present substudy included eligible subjects recruited in the
United States from whom blood was drawn. Analyses performed
as part of this substudy were prespecified in a prospectively
defined analysis plan before the measurement of specimens. Spec-
imens permitted by individual center Institutional Review Board
(IRB) approval and patient consent to unspecified and/or unre-
stricted research use (including time limits) were eligible for
galectin-3 measurement. A total of 654 galectin-3 measurements
at baseline were available. Repeated galectin-3 measurements at
12 months after baseline were available for 394 patients. This
investigation conformed with the principles outlined in the Decla-
ration of Helsinki.
Determination of Biomarkers
Whole blood (EDTA) was shipped on the day of collection, at
room temperature, to a core laboratory for plasma processing
and storage at 80C. Galectin-3 concentrations were determined
from the banked specimens (thawed once) with the use of a com-
mercial enzyme-linked immunosorbent assay (BG Medicine, Wal-
tham, Massachusetts). All laboratory personnel conducting
measurements on specimens were blinded to any patient-level
data. B-Type natriuretic peptide (BNP) measurements were per-
formed for MADIT-CRT by a core laboratory with the use of
the Advia Centaur BNP Assay (Bayer Diagnostics, Tarrytown,
New York).
Study Outcomes and Definitions
The prespecified primary end point of this substudy was the
same as for the overall MADIT-CRT, namely, nonfatal HF event
or death from any cause, whichever occurred first. End point adju-
dication was performed by independent blinded mortality and HF
committees, as described previously.20 The prespecified primary
objective of this substudy was to determine whether subgroupsof subjects defined by baseline galectin-3 level differed in magni-
tude of hazard of the primary end point associated with CRT-D
compared with ICD-only therapy.
Statistical Analysis
Baseline characteristics were compared across galectin-3 quar-
tiles with the use of the Cochran-Armitage trend test for categoric
variables and the Spearman rank correlation test for continuous
variables. Reported pairwise correlation coefficients are Spearman
correlation coefficients.
Cox proportional hazards regression was used to estimate the
hazard ratios (HRs) and 95% confidence intervals (CIs) associated
with treatment group and indicated end points. For categorization
of the baseline galectin-3 variable, restricted cubic spline analysis
was used to formally test the linearity of the relationship between
baseline galectin-3 value and the log-hazard of the primary end
point with the use of the methodology of Harrell,21 and this test
indicated a significant nonlinear relationship (P 5 .003;
Supplemental Fig. 2). The detected nonlinearity occurred at the
4th quartile of the galectin-3 distribution (Supplemental Fig. 2),
and as such the galectin-3 variable was dichotomized using that
value of the distribution as the categorization boundary
(43.3 ng/mL in the present study).22
Evaluation of the interaction test for treatment group by base-
line galectin-3 category in a Cox regression model was performed
by introducing coded variables for treatment group and catego-
rized galectin-3 value, together with the interaction term. Event
rates were analyzed with the use of Poisson regression. Evaluation
of changes from baseline to 12 months in variables was performed
with the use of analysis of covariance regression with the baseline
variable value as a covariate. Multivariable Cox regression models
comprised covariates individually associated with the primary end
point. In Cox regression analyses, Martingale residuals were in-
spected for satisfaction of the linearity assumption of the Cox
regression models. The independence of censoring times and
event was tested by the method of Sun and Lee,23 and no evidence
of dependence between censoring times and event was detected at
a 5% significance level. Risk reclassification was assessed at
18 months with the use of the metric of noncategoric continuous
net reclassification improvement (NRI), with the base model
comprising all covariates in a multivariable Cox regression model
and the enhanced model additionally incorporating galectin-3 as a
natural logarithmically transformed variable.24 c-Statistics for
areas under receiver operating characteristic curves were
compared with the use of the method of deLong et al., which ac-
counts for the correlated nature of the curves.25
All P values are 2 tailed. All analyses were performed with the
use of SAS software, version 9.1 (SAS Institute, Cary, North Car-
olina), or R software, version 2 (R Foundation for Statistical
Computing, Vienna, Austria).Results
Baseline Characteristics
Of the 1,820 subjects enrolled in MADIT-CRT, 654
(35.9%) had a baseline plasma specimen available for mea-
surement of galectin-3. Of these 654 subjects, 386 were
randomized to the CRT-D with ICD (CRT-D) group and
268 to the ICD-only group. There were no significant
differences in baseline characteristics between the
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MADIT-CRT patients with or without galectin-3 measure-
ments (Supplemental Table 1). The clinical characteristics
for all subjects with a baseline galectin-3 measurement,
by quartiles of galectin-3 value, are presented in Table 1.
Higher baseline galectin-3 levels were associated with
larger left ventricular end-systolic volumes (LVESVs)
and end-diastolic volumes (LVEDVs) at baseline, shorter
6-minute walk distance, higher serum creatinine, lower esti-
mated glomerular filtration rate (eGFR), and higher B-type
natriuretic peptide (BNP) levels. The prevalence of hyper-
tension, smoking, and diabetes mellitus was similar across
galectin-3 categories. Baseline galectin-3 levels were
similar between the groups randomized to CRT-D versus
ICD-only (mean 35.2 6 15.8 ng/mL vs 35.0 6 15.9 ng/
mL, respectively; P 5 .85). Considered as a continuous
measure, baseline galectin-3 was weakly correlated with
baseline BNP (correlation coefficient r 5 0.17;
P ! .001) and with serum creatinine (r 5 0.19;
P ! .001) and eGFR (r 5 0.15; P ! .001).
Outcomes
Of the 654 subjects in the present substudy, the primary
end point occurred in 143 subjects (21.9%) during follow-
up. Among these primary events, 113 (79.0%) were first
nonfatal HF events, and 30 (21.0%) were deaths. A total
of 71 deaths occurred in the substudy. During follow-up,
primary events occurred in 69 of the 386 subjectsTable 1. Baseline Characteristics of Sub
Characteristic
All Patients With
Galectin-3 Values
(n 5 654)
Quartile 1
(n 5 164)
Age, y 64.9 (10.7) 64.0 (9.8)
Female sex, n (%) 179 (27) 39 (24)
Body-mass index, kg/m2 29.1 (5.5) 28.8 (4.7)
Systolic blood pressure, mm Hg 122.8 (17.6) 124.9 (17.4)
NYHA II, n (%) 556 (85) 135 (82)
LVEDV, mL 241.4 (60.5) 239.2 (71.3)
LVESV, mL 172.5 (49.0) 172.1 (58.9)
LVEF 0.29 (0.03) 0.29 (0.04)
6-minute walk distance, m 356.0 (113.6) 385.7 (111.6)
LBBB, n (%) 470 (72) 125 (76)
Ischemic etiology, n (%) 336 (51) 78 (48)
Current smoker, n (%) 76 (12) 23 (14)
Medical history, n (%)
Myocardial Infarction 258 (39) 62 (39)
CABG 182 (28) 41 (25)
Hypertension 421 (64) 96 (59)
Diabetes mellitus 204 (31) 37 (23)
Creatinine, mg/dL 1.2 (0.3) 1.0 (0.2)
eGFR (mL min1 1.73 m2) 68.0 (19.4) 75.0 (17.4)
BNP), pmol/L, median (IQR 67 (27e148) 47 (20e101)
Galectin-3, ng/mL, median (IQR) 31.4 (23.5e43.3) 20.0 (17.2e22.0)
Beta-blocker, n (%) 618 (94) 155 (95)
ACE inhibitor, n (%) 505 (77) 129 (79)
Aldosterone antagonist, n (%) 177 (27) 42 (26)
ARB, n (%) 123 (19) 30 (18)
Continuous variables are expressed as mean (SD). NYHA, New York Heart A
LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fract
eGFR, estimated glomerular filtration rate; BNP, B-type natriuretic pept
ARB, angiotensin receptor blocker; na 5 not applicable.(17.9%) randomized to CRT-D and in 74 of the 268 subjects
(27.6%) randomized to ICD-only.Galectin-3, Randomization Group, and Outcomes
CRT-D efficacy in this substudy population was consis-
tent with that of the overall MADIT-CRT (Fig. 1).17
CRT-D was associated with a significantly lower hazard
of primary event compared with ICD-only (unadjusted
HR 0.61, 95% CI 0.44e0.84; P 5 .003). A formal interac-
tion test detected a heterogeneity of CRT-D effect on the
primary end point between high and low galectin-3 cate-
gories (P 5 .045 for interaction; P 5 .027 for interaction
when adjusted for baseline BNP). Among patients with
baseline galectin-3 in the high category, CRT-D was associ-
ated with a 65% reduction in risk of the primary end point
(HR 0.35, 95% CI 0.19e0.67), and among patients with
lower baseline galectin-3 value CRT-D was associated
with a 25% decrease in risk (HR 0.75, 95% CI
0.51e1.11; Fig. 1). Correspondingly, the absolute reduction
in primary event rate attributable to CRT-D, relative to
ICD-only, in the high galectin-3 group was 11.2 fewer pri-
mary events per 100 patient-years (P 5 .001), and in the
low galectin-3 group it was 2.1 fewer primary events per
100 patient-years (P 5 .071). Cumulative incidence curves
for the primary end point by treatment category and by
galectin-3 level among all subjects are shown in Fig. 2.jects by Baseline Galectin-3 Values
Baseline Galectin-3
P Value
for Trend
Quartile 2
(n 5 164)
Quartile 3
(n 5 164)
Quartile 4
(n 5 162)
64.9 (10.4) 65.9 (11.0) 64.4 (11.0) .18
51 (31) 42 (26) 47 (29) .51
28.9 (6.1) 29.1 (5.4) 29.4 (5.5) .28
121.4 (16.8) 123.9 (19.5) 120.8 (16.4) .63
143 (87) 142 (87) 136 (84) .73
233.7 (51.5) 244.8 (59.3) 248.0 (57.9) .008
165.5 (41.4) 175.5 (48.3) 176.9 (45.3) .013
0.30 (0.04) 0.29 (0.04) 0.29 (0.03) .62
347.1 (116.3) 335.5 (105.4) 355.8 (116.0) .009
116 (71) 105 (64) 124 (77) .71
89 (54) 96 (59) 73 (45) .86
16 (10) 19 (12) 18 (11) .55
67 (42) 73 (45) 56 (36) .85
48 (29) 55 (36) 38 (24) .98
104 (63) 116 (71) 105 (65) .13
56 (34) 66 (40) 45 (28) .19
1.2 (0.3) 1.2 (0.3) 1.2 (0.4) .001
67.3 (19.3) 64.9 (18.7) 64.7 (20.0) .001
76 (29e144) 72 (34e182) 89 (35e176) .012
27.1 (25.4e29.0) 36.7 (33.7e39.9) 53.6 (47.4e64.0) na
154 (94) 154 (94) 155 (96) .66
120 (73) 128 (78) 128 (79) .69
42 (26) 43 (26) 50 (31) .29
34 (21) 31 (19) 28 (17) .72
ssociation funcitonal class; LVEDV, left ventricular end-diastolic volume;
ion; LBBB, left bundle branch block; CABG, coronary artery bypass graft;
ide; IQR, interquartile range; ACE, angiotensin-converting enzyme;
Fig. 1. Hazard ratio for primary end point (total mortality or nonfatal heart failure event) by baseline galectin-3 subgroup in all subjects, and
by left bundle branch block (LBBB) status. Event rate indicates the number of primary events per 100 patient-years of follow-up. CRT-D,
cardiac resynchronization therapy with implantable cardioverter-defibrillator; ICD, implantable cardioverter-defibrillator; HR, hazard ratio;
CI, confidence interval.
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most likely to benefit from CRT-D, as it did in the overall
MADIT-CRT (Fig. 1). Among those within the high base-
line galectin-3 category, CRT-D was associated with 14.9
fewer primary events per 100 patient-years (P ! .001),
and among patients in the lower galectin-3 category CRT-
D was associated with 4.3 fewer primary events per 100
patient-years (P 5 .011). Among only patients with
LBBB, a similar heterogeneity of treatment effect was
observed as in the overall substudy (P 5 .072 for interac-
tion; P 5 .029 for interaction when adjusted for baseline
BNP), with patients in the higher galectin-3 category char-
acterized by greater treatment benefit (Fig. 1).
Baseline galectin-3 level was a significant and indepen-
dent predictor of mortality and morbidity in the overall sub-
study cohort (Table 2). In unadjusted Cox proportional
hazards analysis of the primary end point, galectin-3 was
significantly associated with increased hazard of the pri-
mary end point (HR per log unit increase: 1.64; 95% CI
1.13e2.40; P 5 .010). In a multivariable model adjusted
for baseline clinical, cardiac, and demographic parameters
(LVEF, hypertension, NYHA functional class, serum creat-
inine, diabetes, BNP, smoking status, randomization group,
age, and sex), baseline galectin-3 remained significantly
associated with the primary end point (HR per log unit in-
crease: 1.55; 95% CI 1.01e2.38; P 5 .043). Addition of
baseline galectin-3 resulted in moderate net positive reclas-
sification of risk (continuous NRI: þ17%; 95% CI 6%
to þ40%) and improvement in the c-statistic (from 0.72
to 0.75; P 5 .032). On detection of a significant interaction
with treatment randomization group, the association of
galectin-3 with outcome was investigated separately in
the CRT-D and ICD-only groups. Elevated baselinepre-implantation galectin-3 was significantly associated
with the primary outcome in the ICD-only group in a fully
adjusted model, whereas among patients receiving CRT-D a
similar association with outcome was absent (Table 2).
Serial Galectin-3 Measurements
Of the 654 subjects with a baseline galectin-3 measure-
ment, 394 (60.2%) also had a galectin-3 measurement
12 months later. Fifteen subjects (2.3%) died within the first
12 months. Patients who had 12-month galectin-3 measure-
ments did not differ from those who did not have a
12-month galectin-3 measurement in the baseline charac-
teristics of Table 1, and no heterogeneity of treatment effect
was detected based on whether or not a 12-month galectin-
3 measurement was available (P 5 .40 for interaction on
primary end point). Overall, there was a 1.3 ng/mL increase
in mean galectin-3 levels over 12 months across all subjects
and both randomization groups (P 5 .054 for change in
galectin-3 level), and this change was independent from
randomization group (P 5 .36). The increase in galectin-
3 levels over 12 months was dependent on whether or not
a primary event occurred during the interval (P 5 .003):
subjects who experienced an event exhibited on average a
27.7% increase in galectin-3 level between baseline and
12 months (corresponding to a mean 6.8 ng/mL increase;
P 5 .016), whereas subjects who did not experience an
event in the first 12 months exhibited no significant change
in galectin-3 level over that time period (P 5 .20).
Discussion
This substudy of MADIT-CRT investigated plasma
galectin-3 levels in patients who were asymptomatic or
Fig. 2. Cumulative incidence of primary end point by treatment
group in (A) the high (4th quartile) baseline galectin-3 group
and (B) the lower galectin-3 group (!4th quartile). Log-rank
test P values are as indicated in lower right of each figure.
P 5 .045 for interaction between treatment group and baseline
galectin-3 group. Abbreviations as in Fig. 1.
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domized to CRT-D or ICD-only device therapy. We
observed that HF patients with the highest galectin-3 levels
before CRT-D implantation derived a disproportionatelyTable 2. Association of Baseline Galectin-3 With Primary O
Variable
Overall Cohort
HR (95% CI) P Value
Galectin-3 (per log unit increase) 1.64 (1.13e2.40) .010
þ Age, sex 1.66 (1.13e2.44) .009
þ Age, sex, LVEF, NYHA, diabetes
status, smoking status,
hypertension, BNP, serum
creatinine*
1.55 (1.01e2.38) .043
All covariates evaluated at baseline. ICD, implantable cardioverter-defibrillator
confidence interval; other abbreviations as in Table 1.
*Analysis for overall cohort is also adjusted for treatment randomization groularger benefit from CRT-D, evidenced by a statistical inter-
action indicating heterogeneity of CRT-D response by base-
line galectin-3 level. In addition, consistently with results
from more severe HF cohorts, elevated baseline galectin-3
levels were seen to be an independent predictor of adverse
HF outcomes on adjustment for BNP, creatinine, LVEF,
hypertension, NYHA functional class, diabetes, smoking
status, age, and sex. We further observed that the associa-
tion between baseline galectin-3 and adverse HF outcome
risk was significantly attenuated among patients random-
ized to CRT-D in contrast to patients randomized to
ICD-only, in which a significant and independent associa-
tion persisted.
In earlier clinical and experimental studies, circulating
levels of the protein galectin-3 were shown to be associated
with active myocardial fibrogenesis, extracellular matrix
collagen production, and ventricular remodeling.3,5,7,11,12
Lok et al, in a serial echocardiography study of 182 HF pa-
tients, reported that baseline plasma galectin-3 level was
among the most significant and independent predictors of
LVEDV changes over a 4-month period.11 Similarly, Korte-
kaas et al recently reported on a serial echocardiographic
study after surgical mitral valve repair in HF and identified
low baseline plasma galectin-3 concentration as the most
significant predictor of left ventricular reverse remodeling,
defined by change in LVESV over 6 months.12
In the context of predicting response to CRT-D in heart
failure, relatively few studies have investigated the utility
of plasma biomarkers in general, and of biomarkers of fi-
brogenesis and extracellular matrix metabolism in partic-
ular. In the Cardiac Resynchronization in Heart Failure
(CARE-HF) trial, in which 813 patients with class III/IV
HF were randomized to CRT-D or control, baseline levels
of N-terminal pro-BNP (NT-proBNP) retained prognostic
value in both CRT-D and control groups but were not found
to predict response to CRT-D.26 Several other serum bio-
markers were also investigated in a smaller subset of 260
patients in the Cardiac Resynchronization in Heart Failure
(CARE-HF) trial.27 Galectin-3, NT-proBNP, N-terminal
propeptide of type III procollagen, and matrix metallopro-
teinase 1 were associated with $1 outcomes, including
all-cause mortality, death, or HF hospitalization, death
from pump failure, sudden cardiac death, or death, orutcome: Cox Proportional Hazards Regression Results
ICD-Only CRT-D
HR (95% CI) P Value HR (95% CI) P Value
2.20 (1.31e3.68) .003 1.22 (0.70e2.13) .49
2.18 (1.29e3.67) .003 1.31 (0.74e2.31) .35
2.33 (1.25e4.34) .008 1.24 (0.66e2.35) .50
; CRT-D, cardiac resynchronization therapy with ICD; HR, hazard ratio; CI,
p (CRT-D or ICD-only).
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However no statistically significant interaction was found
between any of the tested biomarkers and response to
CRT-D in that study. In an analysis of data from MADIT-
CRT, baseline LVEF was not found to modify the clinical
benefit of CRT-D.28 In contrast, observational studies
have reported associations between elevated baseline levels
of collagen metabolism and positive response to CRT-D.
Garcia-Bolao et al, in 2 study cohorts, observed that
elevated baseline plasma levels of collagen type I carboxy-
terminal propeptide, a marker of collagen synthesis and fi-
brogenesis, predicted response to CRT-D, defined by
reduced cardiac mortality and functional improvement.29,30
The present study is the largest to date to investigate the
relationship of baseline circulating galectin-3 to CRT-D
outcomes. The observation of elevated baseline levels of
galectin-3 among a subset of MADIT-CRT HF subjects is
consistent with the concept of persistent myofibroblast
activation and proliferation characterizing certain HF pa-
tients.31,32 Such persistent myocardial fibrogenic meta-
bolism is believed to play a detrimental role in pathologic
fibrosis, resulting in maladaptive cardiac remodeling,
myocardial stiffness, and worsening HF.33
The observation that patients with elevated pre-
implantation levels of galectin-3 derived disproportionately
greater benefit from CRT-D in the present study is consis-
tent also with earlier studies reporting analogous findings
with elevated collagen synthesis serum markers and CRT-
D response.29,30 Evidence from myocardial biopsies in
HF patients indicates that cardiac resynchronization ther-
apy, in addition to improving intraventricular dyssynchrony
and functional and echocardiographic parameters, induces
significant reverse remodeling at the cellular level, charac-
terized by decreased myocyte size, reduced interstitial
collagen content, and reduced cellular production of proin-
flammatory cytokines, such as tumor necrosis factor a.34,35
Our results may indicate that metabolically active myocar-
dial fibrogenesis may be present in a subset of class I/II HF
patients with LV dyssynchrony, reflected in elevated levels
of circulating galectin-3, and that these patients may derive
disproportionate benefit from the antifibrotic and reverse
myocardial remodeling effects of CRT-D. We observed in
this study of NYHA functional class I and II HF patients
that CRT-D implantation significantly attenuated the associ-
ation of elevated galectin-3 with nonfatal HF event
and death, a result not observed in the ICD-only group.
Moreover, the significant increases in galectin-3 levels
over 12 months were seen predominantly among patients
experiencing adverse outcomes, further supporting the hy-
pothesis that CRT-D may ameliorate persistent fibrogenesis
and active collagen metabolism at a fundamental cellular
and molecular level in the myocardium of failing hearts.Study Limitations
Although MADIT-CRT was a multinational study, blood
samples were collected in the United States only, andgalectin-3 was measured only in samples from which indi-
vidual center IRB approval and patient consent for unre-
stricted research was obtained. This limited the sample
size. The present study was a retrospective analysis of spec-
imens and associated data from a completed trial. In this
study, samples were drawn at the clinical sites and shipped,
on the day of collection, to the core lab as whole blood at
room temperature. The protein galectin-3 has been demon-
strated to be stable for up to 22 days at room temperature
(22

Ce28

C), and prolonged storage of whole blood for
O8 hours has been associated with stable but finite leakage
of intracellular galectin-3 and other proteins in specimens
handled in this manner.36e38 As such, the absolute levels
of galectin-3 reported in this work may be elevated relative
to those reported elsewhere. Despite an inability to combine
and compare absolute values across studies, our findings are
based on relative concentrations, and are consistent with the
outcome of other HF studies and CRT-D trials.8,10,27Conclusion
Elevated galectin-3 was found to be a significant and in-
dependent predictor of adverse HF outcome in patients with
mildly symptomatic HF. In the present study, patients with
galectin-3 values in the highest quartile also derived a
disproportionately larger benefit from CRT-D. These data
suggest that galectin-3 might identify the highest-risk pa-
tients who may derive the greatest absolute benefit from
CRT-D, and prospective confirmatory trials to that end
may be warranted.Acknowledgments
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